Meridian Bioscience has secured authorisation from the US Food and Drug Administration (FDA) to market a new test for the detection of cytomegalovirus (CMV) in newborns.

The new Alethia CMV Assay Test System is designed to identify CMV deoxyribonucleic acid (DNA) from saliva swabs to diagnose congenital CMV infection.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A report by the US’ Centre for Disease Control and Prevention (CDC) showed that more than 50% of adults have had a CMV infection by age 40. While the majority of infected people do not display signs or symptoms, those with weakened immune systems and newborns may experience serious health issues.

The FDA’s office of in-vitro diagnostics (IVD) and radiological health director Tim Stenzel said: “Although most people who become infected with CMV face little to no risk of serious illness, the virus has the potential to cause serious illness for people with weak immune systems and in newborn babies.

“The virus has the potential to cause serious illness for people with weak immune systems and in newborn babies.”

“This test for detecting the virus, when used in conjunction with the results of other diagnostic tests, may help healthcare providers more quickly identify the virus in newborns and determine the best approach for the child.”

The FDA reviewed Alethia CMV Assay Test System’s analytical and clinical data, including findings from a prospective clinical study.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

During the study, the device was able to correctly detect 1,472 out of the total 1,475 saliva samples from newborns as negative for CMV DNA. Three specimens were incorrectly identified and five were correctly detected as positive for the presence of the DNA.

The regulatory agency also evaluated results from 34 samples of archived specimens from babies with known CMV infection. The device was able to correctly identify all the specimens as positive.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact